Why Inovio Stock Is Still a Buy After a 20% Dip

Editor's Note: Private Briefing premium subscribers get access to many more winners like Inovio. Find out how to get access to this exclusive research and analysis put together by our esteemed Executive Editor, Bill Patalon. Learn more here.

One of our favorite biotech stocks, Inovio Pharmaceuticals Inc. (Nasdaq: INO), has seen a steep fall lately. Inovio stock is down 20.5% since it reached a 2015 high of $10.77 on April 22.

Even with this recent slip, INO is still one of our biggest triple-digit winners. Inovio stock is up 241% since Money Morning's Executive Editor Bill Patalon first recommended it to his readers in February 2013.

A 20% drop can send investors running for the exits. But now is not the time to panic and sell. Inovio stock remains a long-term stock to buy.

Here's why.

What's Going On with Inovio Stock

Inovio StockInovio is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and vaccines for infectious diseases. While cancer is the company's primary focus, it's also developing treatments for hepatitis C, hepatitis B, HIV, malaria, and Ebola.

The company is at the forefront of "synthetic" vaccine technology. Most vaccines we use today were developed decades ago. Synthetic vaccines are easier to engineer, and they use no chemicals, no additives, and no preservatives.

The firm has some big-name partners. Bill and Melinda Gates' anti-malaria foundation has donated millions to Inovio's malaria efforts in recent years. In April 2015, the Defense Advanced Research Projects Agency (DARPA) awarded Inovio a $45 million grant for its Ebola research. It also won two grants from the National Institutes of Health in 2015 that totaled $28 million.

These are good signs for Inovio's future. But there are a couple reasons for INO's recent pullback...

One reason for the decline in Inovio stock was the company's Q1 earnings report.

In the first quarter, INO generated $5.17 million in revenue. While that was 119% higher than the previous year, investors were disappointed because Wall Street had predicted revenue of $7 million.

Earnings per share (EPS) also missed expectations. The company reported a loss of $0.17 per share, when Wall Street had expected a miss of just $0.11 per share.

This was the second straight quarter that INO stock missed EPS estimates. In Q4 2014, INO missed Wall Street expectations by 20%.

Looking forward, the company is expected to have an EPS loss of $0.16 in the upcoming quarter. That's wider than the $0.12 loss it had last year.

But EPS misses aren't the only reason INO stock dipped 20% in the last month. On April 30, the stock fell more than 17% after the company made this decision...

Behind Inovio Stock's Plunge and Where It's Headed

On April 30, Inovio officials announced the pricing of an underwritten public offering of the company's common stock.

Through the deal, 9.5 million shares of INO debuted at $8 per share. The announcement sent shares from a closing price of $9.85 on April 29 to a closing price of $8.16 on April 30.
But this type of movement is quite common following an additional offering of shares. As more shares are added, the power of the original shares are diluted. While this clearly upset some of the original investors who sent the Inovio stock price lower, it's not a deal breaker.

[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]According to Patalon, Inovio stock still offers plenty of upside.

"Inovio has a unique technology that's demonstrated tangible benefits in testing, and a strong, passionately committed management team," Patalon said. "But investors need to look at this as a long-term investment. It's a stock that will be volatile, as most high-risk/high-return stocks tend to be."

Wall Street also sees the value in Inovio stock.

Six analysts surveyed by Thomson/First Call have an average price target of $21 for Inovio stock. Hitting that target would be a gain of 145%. The most bullish price target is $31, which would be a gain of 262%.

Shares opened today at $8.56. You can see the volatility in the stock's beta, which is 2.79.

The Bottom Line: Inovio stock has climbed more than 240% since we first recommended it in February 2013. And despite a 20% drop in the last month, INO shares still offer plenty of upside. The company is at the forefront of synthetic vaccine technology and is working to combat numerous infectious diseases and cancer. For investors willing to take on some risk, this is a good long-term stock to buy and hold.


Follow me on Twitter: @KyleAndersonMM

Double Your Money on the World's Most Valuable Company: Money Morning's Tom Gentile has found one small move that can help you make a 100% profit on a popular stock, all within the next 27 days. Here's how you can find out the step-by-step process to doubling your money...